1. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (June 2017) Authors: Casasnovas, R.; Westin, J.; Thieblemont, C.; Zijlstra, J.; Hill, B.; De La Cruz Vicente, F.; Choquet, S.; Caimi, P.; Kaplan, J.; Canales, M.; Kuruvilla, J.; Follows, G.; van den Neste, E.; Meade, J.; Wrigley, B.; Devlin, M.; Saint‐Martin, J.; Nippgen, C.; Gardner, H.; Shacham, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR). (December 2016) Authors: Chowdhury, S.; Burris, H.A.; Patel, M.; Infante, J.R.; Jones, S.F.; Voskoboynik, M.; Parry, K.; Elvin, P.; Coleman, T.; Gardner, H.; Lyne, P.D.; Arkenau, H.T. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Canine oral fibrosarcomas: a retrospective analysis of 65 cases (1998–2010)1. (18th February 2013) Authors: Gardner, H.; Fidel, J.; Haldorson, G.; Dernell, W.; Wheeler, B. Journal: Veterinary and comparative oncology Issue: Volume 13:Number 1(2015:Mar.) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗